Eisai Completes Submission of LEQEMBI® (lecanemab-irmb)

Eisai Completes Submission of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA

/PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge,...

Related Keywords

Taiwan , India , Hong Kong , Japan , Israel , Massachusetts , United States , Tokyo , Cambridge , Cambridgeshire , United Kingdom , Brazil , Australia , Saudi Arabia , Switzerland , China , Russia , Singapore , Canada , South Korea , Great Britain , Libby Holman , Jack Cox , Chuck Triano , Christophera Viehbacher , Haruo Naito , Tsujim Protofibrils , Eisai Inc , Facebook , Prnewswire Eisai Co Ltd , Exchange Commission , Youtube , Eisai Co Ltd , Linkedin , European Union , Eisai Europe Ltd , Drug Administration , Biogen Inc , Nasdaq , United Nations Sustainable Development Goals Sdgs , Public Relations Department , Communications Department , Investor Relations Department , Supplemental Biologics License Application , Biologics License Application , Fast Track , Breakthrough Therapy , Mild Cognitive Impairment , Dose Management , Antithrombotic Medication , Risk Factors , Intracerebral Hemorrhage , Prescribing Information , Relations Department , Clinical Dementia Rating Sum , Corporate Concept , United Nations Sustainable Development Goals , Important Targets , Disease Modifying Approach , Intj Mol , Accelerated Approval , Japan Available , Early Alzheimer , New England Journal ,